½ÃÀ庸°í¼­
»óǰÄÚµå
1346810

¼¼°èÀÇ ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)

Global Oxycodone Hydrochloride Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 231 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿Á½ÃÄÚµ·¿°»ê¿°(¿°»ê¿Á½ÃÄÚµ·, Oxycodone Hydrochloride) ½ÃÀå ¼ö¿ä´Â 2022³âÀÇ 4¾ï 623¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 6¾ï 1,265¸¸ ´Þ·¯ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2023-2030³â CAGRÀº 5.27%·Î ÃßÀÌÇÏ¸ç ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿Á½ÃÄÚµ·¿°»ê¿°Àº °­·ÂÇÑ ¿ÀÇÇ¿ÀÀ̵å ÁøÅëÁ¦·Î Áߵ¿¡¼­ ÁßÁõ ÅëÁõ °ü¸®¿¡ »ç¿ëµË´Ï´Ù. ¿ÀÇÇ¿ÀÀ̵å ÀÛ¿ëÁ¦·Î ¾Ë·ÁÁø ¾àÈ¿ ºÐ·ù¿¡ ¼ÓÇÕ´Ï´Ù. ´Ù¾çÇÑ ±â°£¿¡ °ÉÃÄ ÁøÅë È¿°ú¸¦ ¹ßÈÖÇϱâ À§ÇØ Áï½Ã ¹æÃâÇü°ú ¼­¹æÇü µî ´Ù¾çÇÑ Á¦Á¦°¡ ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÁÖ·Î ÀÇ·á óġ ÈÄ ¼ö¼ú ÈÄ ¿Ü»ó, ºÎ»ó, ¾Ï °ü·Ã ÅëÁõ µî Áߵ¿¡¼­ ÁßÁõÀÇ ÅëÁõÀÇ °æ¿ì È¿°úÀûÀÎ ÅëÁõ °ü¸®ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ´Â °ÍÀÌ ¹è°æ¿¡ ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ¸¸¼º ÅëÁõ ÁúȯÀÇ ¸¸¿¬ÀÌ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á Á¾»çÀÚÀÇ Ã³¹æ ½À°ü, °Ç°­ °ü¸® ÀÎÇÁ¶ó ¹× ÅëÁõ °ü¸® ¿É¼Ç¿¡ ´ëÇÑ ÀǽÄÀº »ç¿ë·ü¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, Á¦¾à »ê¾÷ÀÇ ¿ªÇÐ, ¿ÀÇÇ¿ÀÀ̵å ó¹æ¿¡ °üÇÑ °¡À̵å¶óÀεµ ÇѸòÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¹ßÀüÀº ÅëÁõ ¿ÏÈ­ÀÇ ¿ä±¸¿Í °ü·ÃµÈ À§Çè°ú µµÀü°úÀÇ ±ÕÇüÀ» À¯ÁöÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ³ë·ÂÀ̶ó´Â ¸Æ¶ô¿¡¼­ ÀÌÇØµÇ¾î¾ß ÇÕ´Ï´Ù. ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀåÀÇ ÇöÀç »óŸ¦ ÀÌÇØÇϱâ À§Çؼ­´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â ÀÇ·á¿øÀ» ÅëÇØ Ç×»ó Á¤º¸¸¦ ¾ò´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ì´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â »ê¾÷ÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀï ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿Á½ÃÄÚµ·¿°»ê¿° »ê¾÷ ¼ºÀå ¹× µ¿ÇâÀº ÀÌ ¿¬±¸¿¡ Àü¹ÝÀûÀÎ Á¢±ÙÀ» Á¦°øÇÕ´Ï´Ù.

Áö¿ª ºÐ¼® :

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾Æ ÅÂÆò¾ç, ³²¹Ì, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÁßÁ¡À» µÓ´Ï´Ù.

Ưº° ÁÖ¹® ¿äûÀÌ ÀÖÀ¸½Ã¸é ´ç»ç¿¡ ¹®ÀÇÇϽʽÿÀ. ´ç»çÀÇ ¿¬±¸Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ½ÃÀå ÇöȲ

Á¦3Àå ¿Á½ÃÄÚµ·¿°»ê¿°-»ê¾÷ ºÐ¼®

  • ¼Ò°³-½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ
  • ±âȸ
  • »ê¾÷ µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸ñ·Ï
    • ¿øÀç·á Á¦Á¶»ç ¸ñ·Ï
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ±¸¸ÅÀÚ ¸ñ·Ï
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå ºÐ¼® : À¯Çüº°

  • À¯Çüº° °³¿ä
  • ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • À¯Çüº° ºÐ¼®
  • ¹æÃâ Á¦¾îÇü(¼­¹æÇü)
  • Áï°¢ ¹æÃâÇü

Á¦6Àå ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

  • Åõ¿© °æ·Îº° °³¿ä
  • ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • Åõ¿© °æ·Îº° ºÐ¼®
  • °æ±¸
  • ºñ°æ±¸

Á¦7Àå ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå ºÐ¼® : À¯Åë ä³Îº°

  • À¯Åë ä³Îº° °³¿ä
  • ½ÇÀû ¹× ¿¹Ãø µ¥ÀÌÅÍ
  • À¯Åë ä³Îº° ºÐ¼®
  • º´¿ø
  • ¼Ò¸Å ¾à±¹

Á¦8Àå ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼Ò°³
  • ºÏ¹Ì ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾Æ ÅÂÆò¾ç
  • ³²¹Ì ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • ³²¹Ì : ºÎ¹®º°
    • ³²¹Ì : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû ¹× ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä« °øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ¿Á½ÃÄÚµ·¿°»ê¿° ±â¾÷ °æÀï ±¸µµ

  • ¿Á½ÃÄÚµ·¿°»ê¿° ½ÃÀå °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Eli Lilly and Co.
  • Gilead Sciences Inc.
  • Manus Aktteva Biopharma LLP
  • Arevipharma
  • Saneca Pharma
  • Cipla Ltd
  • Noramco
  • Macfarian Smith
  • Teva Pharmaceutical Industries Ltd
  • Taj Pharma
  • Chattem Chemicals Inc.
  • Mayne Pharma Group Limited
  • Dr. Reddy's Laboratories Ltd
  • Siegfried
  • Rhodes Pharmaceuticals
  • Mallinckrodt Plc
  • Johnson&Johnson
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Sanofi Sais
LYJ 23.10.13

The global demand for Oxycodone Hydrochloride Market is presumed to reach the market size of nearly USD 612.65 MN by 2030 from USD 406.23 MN in 2022 with a CAGR of 5.27% under the study period 2023 - 2030.

Oxycodone hydrochloride is a powerful opioid analgesic medication used to manage moderate to severe pain. It belongs to the class of medications known as opioid agonists. It is available in various formulations, including immediate-release and extended-release versions, to provide pain relief over different time periods.

MARKET DYNAMICS:

The growth of the oxycodone hydrochloride market is influenced by several factors. It is primarily driven by the increasing need for effective pain management in cases of moderate to severe pain, such as after medical procedures, surgeries, trauma, injury, and cancer-related pain. The aging global population and the prevalence of chronic pain conditions contribute to the rising demand. Medical professionals' prescription practices, healthcare infrastructure, and awareness about pain management options impact its utilization. Regulatory frameworks, pharmaceutical industry dynamics, and guidelines for opioid prescription also play a role. The market's evolution must be understood in the context of the ongoing efforts to balance pain relief needs with the associated risks and challenges. Staying informed through reliable medical sources is essential for understanding the current state of the oxycodone hydrochloride market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of oxycodone hydrochloride. The growth and trends of oxycodone hydrochloride industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the oxycodone hydrochloride market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • Controlled-Release
  • Immediate-Release

By Route Of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospitals
  • Retail Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Oxycodone Hydrochloride market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Oxycodone Hydrochloride market include Eli Lilly and Co., Gilead Sciences Inc., Manus Aktteva Biopharma LLP, Arevipharma, Saneca Pharma, Cipla Ltd, Noramco, Macfarian Smith, Teva Pharmaceutical Industries Ltd, Taj Pharma, Chattem Chemicals Inc., Mayne Pharma Group Limited, Dr. Reddy's Laboratories Ltd, Siegfried, Rhodes Pharmaceuticals, Mallinckrodt Plc, Johnson & Johnson, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd, Lupin Ltd, and Sanofi Sais. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . OXYCODONE HYDROCHLORIDE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL OXYCODONE HYDROCHLORIDE MARKET ANALYSIS BY TYPE

  • 5.1 Overview by Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Type
  • 5.4 Controlled-Release Historic and Forecast Sales by Regions
  • 5.5 Immediate-Release Historic and Forecast Sales by Regions

6 . GLOBAL OXYCODONE HYDROCHLORIDE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1 Overview by Route of Administration
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Route of Administration
  • 6.4 Oral Historic and Forecast Sales by Regions
  • 6.5 Parenteral Historic and Forecast Sales by Regions

7 . GLOBAL OXYCODONE HYDROCHLORIDE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1 Overview by Distribution Channel
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Distribution Channel
  • 7.4 Hospitals Historic and Forecast Sales by Regions
  • 7.5 Retail Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL OXYCODONE HYDROCHLORIDE MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE OXYCODONE HYDROCHLORIDE COMPANIES

  • 9.1. Oxycodone Hydrochloride Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF OXYCODONE HYDROCHLORIDE INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Eli Lilly and Co.
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Gilead Sciences Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Manus Aktteva Biopharma LLP
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Arevipharma
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Saneca Pharma
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Cipla Ltd
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Noramco
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Macfarian Smith
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Teva Pharmaceutical Industries Ltd
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Taj Pharma
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Chattem Chemicals Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments
  • 10.14. Mayne Pharma Group Limited
    • 10.14.1. Company Overview
    • 10.14.2. Company Revenue
    • 10.14.3. Products
    • 10.14.4. Recent Developments
  • 10.15. Dr. Reddy's Laboratories Ltd
    • 10.15.1. Company Overview
    • 10.15.2. Company Revenue
    • 10.15.3. Products
    • 10.15.4. Recent Developments
  • 10.16. Siegfried
    • 10.16.1. Company Overview
    • 10.16.2. Company Revenue
    • 10.16.3. Products
    • 10.16.4. Recent Developments
  • 10.17. Rhodes Pharmaceuticals
    • 10.17.1. Company Overview
    • 10.17.2. Company Revenue
    • 10.17.3. Products
    • 10.17.4. Recent Developments
  • 10.18. Mallinckrodt Plc
    • 10.18.1. Company Overview
    • 10.18.2. Company Revenue
    • 10.18.3. Products
    • 10.18.4. Recent Developments
  • 10.19. Johnson & Johnson
    • 10.19.1. Company Overview
    • 10.19.2. Company Revenue
    • 10.19.3. Products
    • 10.19.4. Recent Developments
  • 10.20. Bristol-Myers Squibb Company
    • 10.20.1. Company Overview
    • 10.20.2. Company Revenue
    • 10.20.3. Products
    • 10.20.4. Recent Developments
  • 10.21. Sun Pharmaceutical Industries Ltd
    • 10.21.1. Company Overview
    • 10.21.2. Company Revenue
    • 10.21.3. Products
    • 10.21.4. Recent Developments
  • 10.22. Lupin Ltd
    • 10.22.1. Company Overview
    • 10.22.2. Company Revenue
    • 10.22.3. Products
    • 10.22.4. Recent Developments
  • 10.23. Sanofi Sais
    • 10.23.1. Company Overview
    • 10.23.2. Company Revenue
    • 10.23.3. Products
    • 10.23.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦